Scenarios Requiring Enhanced Due Diligence

Published on 21/12/2025

When to Apply Enhanced Due Diligence in Vendor Oversight

Table of Contents

Introduction: Standard vs Enhanced Due Diligence

Vendor due diligence is a cornerstone of outsourcing in clinical trials. While most vendors undergo routine qualification, certain situations demand enhanced due diligence—a deeper, risk-focused evaluation that goes beyond questionnaires and basic audits. Enhanced due diligence is applied when vendors pose higher risks to patient safety, data integrity, or regulatory compliance. Sponsors must identify these scenarios proactively and tailor oversight strategies accordingly. Regulatory authorities expect enhanced evaluations for critical, high-risk, or non-traditional vendors.

1. Regulatory Expectations for Enhanced Due Diligence

Global frameworks emphasize risk-based oversight that justifies deeper assessments when risks increase:

ICH-GCP E6(R2): Sponsors must implement risk-based quality management, extending to vendors.
FDA BIMO Guidance: Sponsors remain accountable for vendor performance and compliance, requiring deeper evaluation of high-risk partners.
EMA Reflection Papers: Highlight enhanced oversight for critical vendors handling safety data, IMPs, or primary endpoints.

Regulators often ask sponsors to justify why enhanced due diligence was or was not applied during inspections.

2. Scenarios Requiring Enhanced Due Diligence

Enhanced due diligence is necessary in multiple contexts:

Critical Vendors: CROs, central labs, pharmacovigilance vendors, and IMP manufacturers directly impacting patient safety and data integrity.
Vendors with Poor Regulatory History:

Prior FDA 483s, EMA inspection findings, or CAPAs not fully implemented.

Vendors in Emerging Markets: Countries with less mature regulatory oversight or high variability in compliance culture.

New or Unproven Vendors: Startups with limited experience in regulated trials or no inspection history.

Vendors Handling Sensitive Data: Cloud-based providers managing eCRFs, patient registries, or genomic data subject to GDPR/HIPAA.

Financially Unstable Vendors: Vendors showing liquidity risks, delayed payments, or dependency on a single client.

Subcontractor-Dependent Vendors: Vendors heavily outsourcing critical functions to third parties without strong oversight.

3. Enhanced Due Diligence Checklist

An enhanced checklist goes beyond standard qualification requirements and may include:

Domain	Enhanced Review Requirement
Quality Management	On-site audit of QMS, SOP review, CAPA tracking
Regulatory History	Detailed review of inspection reports and follow-up actions
Data Integrity	Validation of IT systems, cybersecurity penetration testing
Financial Stability	Audited financials, credit reports, business continuity plans
Staffing	Verification of GCP training, turnover analysis, succession planning
Subcontractors	Review of subcontractor qualification and monitoring processes

4. Case Study: Enhanced Due Diligence for a Data Vendor

Scenario: A sponsor evaluating a cloud-based EDC vendor discovered through initial due diligence that the vendor had limited inspection history and no formal data breach response SOPs.

Resolution: The sponsor applied enhanced due diligence, requiring an on-site IT audit, third-party cybersecurity certification, and quarterly CAPA follow-ups. The vendor was conditionally qualified with ongoing oversight, ensuring data privacy compliance under GDPR and HIPAA.

5. Benefits of Enhanced Due Diligence

While resource-intensive, enhanced due diligence provides critical benefits:

Mitigates high-risk compliance gaps before vendor engagement.
Strengthens inspection readiness with documented justifications.
Enhances data security and patient safety in critical vendor operations.
Protects sponsors from reputational and financial risks tied to vendor failures.

6. Best Practices for Sponsors

Define risk triggers for enhanced due diligence in SOPs.
Engage cross-functional teams (QA, IT, Clinical Operations, Legal) in evaluations.
Document all enhanced due diligence activities in the TMF for inspection readiness.
Reassess vendors periodically, especially after regulatory findings or organizational changes.
Use risk scoring systems to justify the application of enhanced evaluations.

Conclusion

Enhanced due diligence is a vital tool for mitigating vendor risks in clinical trials. Scenarios such as critical vendor engagement, poor compliance history, emerging market operations, or sensitive data handling require deeper oversight beyond standard qualification. By applying enhanced due diligence frameworks, documenting processes in the TMF, and aligning with FDA and EMA expectations, sponsors can ensure reliable vendor partnerships, regulatory compliance, and trial integrity in global outsourcing models.